Obesity Update: Ascletis’ ASC30, Hanmi’s CRF2 Breakthrough, Orforglipron’s 27-Pound Loss, Mounjaro’s Korea Launch & More
In this week’s Obesity Updates, we spotlight pivotal developments transforming obesity care—from novel GLP-1 alternatives and dual-action therapies to aggressive pricing, IPO surges, and bold market expansions.
🔬 Key Highlights This Week:
🧪 Ascletis completes fast U.S. Phase 2a enrollment for oral GLP-1R agonist ASC30.
💪 Hanmi advances CRF2-targeting drug for fat loss and muscle gain.
⏳ MetaVia extends DA-1726 Phase 1 dosing to eight weeks.
📉 Chugai shares drop 20% after underwhelming trial data.
💊 Lilly’s Orforglipron delivers 27.3 lbs weight loss in Phase 3.
🇨🇳 Novo Nordisk upbeat on China despite 11% semaglutide sales dip.
🇰🇷 Mounjaro to debut in Korea at 25% discount to Wegovy.
🚀 Nxera launches proprietary obesity pipeline.
📈 G2G Bio IPO oversubscribed 810 times.
💰 Innogen raises $87M in Hong Kong IPO.
Whether you’re a clinician, investor, or strategist in obesity therapeutics, this episode delivers fast, expert-curated insights into the future of weight loss innovation.
📢 Stay Ahead in Obesity Research!
✅ Like, share, and subscribe for weekly updates
#ObesityResearch #GLP1 #ClinicalTrials #Orforglipron #Mounjaro #ASC30 #CRF2 #Lilly #NovoNordisk #BiotechNews #LucidQuest #WeightLossDrugs #HealthcareInnovation #PharmaNews #GlobalHealth